New Zebrafish Bioassay Accelerates Screening for Melanotrophic Drug Candidates

Melanin, the primary pigment in skin, hair, and eyes, plays a crucial role in UV protection and is implicated in various dermatological conditions like hyperpigmentation (e.g., melasma) and hypopigmentation (e.g., vitiligo), as well as melanoma. Developing new therapeutics for these conditions requires efficient methods to identify compounds that modulate melanin production, known as melanotrophic compounds. However, current screening methods often lack the throughput or physiological relevance needed for early-stage drug discovery. This study addresses the critical need for a rapid, cost-effective, and in vivo screening platform to identify novel melanotrophic therapeutic candidates.

The developed zebrafish bioassay demonstrated high sensitivity and specificity in detecting changes in melanin production. It accurately identified known pro-melanogenic compounds, showing a significant increase in melanin content by up to 48% at 5 µM compared to vehicle control (p<0.001). Conversely, known anti-melanogenic agents induced a dose-dependent reduction in melanin, with some compounds achieving a 65% decrease at 10 µM (p<0.0001). The assay exhibited a robust Z'-factor of 0.78, indicating excellent suitability for high-throughput screening. This novel zebrafish bioassay achieved a 3.2-fold increase in screening throughput compared to traditional cell-based assays, accurately identifying both pro- and anti-melanogenic compounds with an overall sensitivity of 93% and specificity of 89% against a panel of validated agents. Furthermore, the assay showed excellent reproducibility across multiple independent experiments, with a coefficient of variation consistently below 10%.